ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells
more
Push For Smart Industry: ChromoTek wins category "Biotechnology" and the overall first prize from 1200 participating companies.
more
Visit us at the annual meeting of the American Association for Cancer Research, booth 1038!
moreChromoTek's Chromobody® Technology for High Content drug profiling licensed to Bayer
more
Chromobodies®
ChromoTek's Chromobodies® are a novel species of extremely small intracellular functional antibodies. Chromobodies® are based on the antigen binding domain (VHH) derived from heavy chain antibodies of camelids genetically fused to a fluorescent protein (e.g.TagGFP or TagRFP from Evrogen). As opposed to conventional antibodies, these innovative fluorescent nanoprobes are suitable for real time analyses and can visualize endogenous cellular structures and processes in live cells.
Thus, Chromobodies® are the perfect reagents for cellular research including High-Content Analysis (HCA).
In addition to stable cell lines, you can also obtain the Chromobody® plasmid which allows you to create your own cell lines or transiently express the Chromobody®.
All Chromobody® binding domains are carefully selected to not interfere with endogenous protein function and offer the unique possibility to trace native proteins in living cells.
